| Similar Articles |
|---|
 |
The Motley Fool
January 18, 2008
Brian Orelli |
The Battle of the Thrombins ZymoGenetics announces that its recombinant thrombin product, Recothrom, was given a thumbs-up by the FDA.   |
The Motley Fool
May 13, 2008
Brian Orelli |
Omrix's Wild Ride High-growth stocks like Omrix Pharmaceutical can be hard to value. Not only are growing revenues hard to predict, but expenses can fluctuate wildly as the company grows. |
The Motley Fool
August 23, 2007
Brian Orelli |
Can't Stop the Bleeding From a Paper Cut ZymoGenetics' rThrombin product is delayed. With a 9% drop in stock price, it looks like investors are overreacting. |
Managed Care
December 2007
Thomas Morrow |
Human-Derived Clotting Agent Avoids Immunogenicity Evithrom may minimize some of the antibody production associated with bovine proteins, but the possibility of human viral infection exists. |
The Motley Fool
August 21, 2009
Brian Orelli |
ZymoGenetics Goes in for the Kill ZymoGenetics went on the offensive, asking the Food and Drug Administration to pull competitor King Pharmaceuticals' Thrombin-JMI off the market. |
The Motley Fool
September 6, 2007
Brian Orelli |
Foolish Fantasy Football: 3 Drug Companies The pro football season kicks off tonight. Our fantasy team might just help you tear up the investing gridiron! Here's the starting lineup. Barr Pharmaceuticals... GlaxoSmithKline... etc. |
The Motley Fool
September 6, 2006
Brian Lawler |
Catalyst for ZymoGenetics? Trial results for a drug that controls bleeding include a favorable comparison with a similar product. Investors, take note. |
The Motley Fool
November 5, 2008
Brian Orelli |
ZymoGenetics Leads With Its Chin It says a lot about ZymoGenetics' quarter that management decided to open its conference call talking about its hepatitis C drug still in trials, rather than the sales results of its blood-clotting agent, Recothrom. |
The Motley Fool
May 16, 2007
Mike Havrilla |
ZymoGenetics Is Poised to Stop Bleeding With shares of ZymoGenetics currently trading near three-year lows, now may be a good time to pick some up. |
The Motley Fool
January 14, 2009
Brian Orelli |
ZymoGenetics, the Pharmaceutical Zombie ZymoGenetics deal with Bristol-Myers may bring the drug developer stumbling back from the dead. |
The Motley Fool
September 7, 2010
Luke Timmerman |
ZymoGenetics, Seattle Biotech Pioneer, Acquired by Bristol-Myers for $885 Million The two companies have gotten to know each other quite well since January 2009, when Bristol agreed to pay as much as $1.1 billion for the right to co-develop and co-market a drug for hepatitis C. |
The Motley Fool
May 1, 2007
Mike Havrilla |
Heads Up, Biotech Investors Big news is in the offing for these companies. Pozen... Progenics... Zymogenetics... etc. |
The Motley Fool
August 6, 2007
Brian Orelli |
Congress' Delay May Hurt Drugmakers The reauthorization of the Prescription Drug User Fee Act is delayed. If you're an investor in drug companies, now might be a good time to call your representatives and senators. |
The Motley Fool
September 30, 2010
Brian Orelli |
Bristol-Myers' Delayed Steal ZymoGenetics price tag looks more reasonable. |
The Motley Fool
November 6, 2006
Brian Lawler |
One Step at a Time ZymoGenetics' management is still facing challenges, but so far it has proved itself worthy to investors. |
The Motley Fool
September 18, 2007
Brian Orelli |
PDUFA Reauthorization: Almost There Much to the applause of drug makers and those who invest in them, the Prescription Drug User Fee Act reauthorization looks like it could come out of a Congressional conference committee as early as this week. |
